thebeach,
I think one that people should be looking at is:
dimethaid.com
Subject 4878
stockhouse.ca
With their recent success in getting a full market license in the UK, which opens most of Europe to them also (300 million + people), I believe this is one to watch.
In the recent market turmoil, while most companies have been watching their valuations get killed, DMX has added about 70% in the last week alone.
They have had a bit of a bumpy ride in the last year, but with this recent approval and with a marketing partner (hopefully soon) in the UK, we should see some nice gains.
This of course does not include their immunomodulator drug WF10, which is in late stage phase III trials for AIDS in the US and Canada. If the phase III results are anything like the phase II, then WF10 will be very well received. It is in various stages of trials in Europe and the USA for other applications such as prostate cancer, lymphoma and hepatitis C. I suspect other trials are going to be starting soon for MS, and perhaps Crohn's disease, where there has been anecdotal information of success.
I am not an expert in the valuation of pharmas - I know a little about the science - but my sense tells me that if things come together on only 2-3 fronts for DMX, they are going to be a winner.
MB |
